|
|
Volumn 373, Issue 9663, 2009, Pages 541-542
|
|
Gefitinib plus docetaxel in non-small-cell lung cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR;
GEFITINIB;
ANTINEOPLASTIC AGENT;
PROTEIN KINASE INHIBITOR;
QUINAZOLINE DERIVATIVE;
TAXOID;
TUMOR MARKER;
CLINICAL TRIAL;
DATA ANALYSIS;
DEMOGRAPHY;
GENE;
HUMAN;
LETTER;
LUNG NON SMALL CELL CANCER;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
DRUG EFFECT;
GENETICS;
LUNG TUMOR;
MORTALITY;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
BIOASSAY;
SURVIVAL RATE;
ANTINEOPLASTIC AGENTS;
CARCINOMA, NON-SMALL-CELL LUNG;
HUMANS;
LUNG NEOPLASMS;
PROTEIN KINASE INHIBITORS;
QUINAZOLINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RECEPTOR, EPIDERMAL GROWTH FACTOR;
TAXOIDS;
TUMOR MARKERS, BIOLOGICAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ENDPOINT DETERMINATION;
SURVIVAL RATE;
|
|
EID: 59749088514
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(09)60194-X Document Type: Letter |
|
Times cited : (3)
|
|
References (2)
|
